Last updated on May 2019

Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

Brief description of study

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day and 16 mg/day in the treatment of subjects with early Alzheimer's Disease compared to placebo.

Clinical Study Identifier: NCT03446001

Find a site near you

Start Over

The Roskamp Institute, Inc.

Sarasota, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.